© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health
September 22, 2022
Jeremy Tan, MD, discusses the latest trends in eye trauma surgery at the Dean McGee Eye Institute.
September 20, 2022
At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.
September 18, 2022
Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.
August 30, 2022
David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.
August 30, 2022
Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.
August 30, 2022
Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.
August 30, 2022
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.
August 30, 2022
Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.
August 30, 2022
Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.
August 30, 2022
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.